ArticleJournal of computer-aided molecular design2022
Multi-task convolutional neural networks for predicting in vitro clearance endpoints from molecular images.
Article in Journal of computer-aided molecular design, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A review on integrated machine learning and deep learning driven artificial intelligence models for pharmacokinetics and toxicokinetics predictions, and their application.Drug metabolism and disposition: the biological fate of chemicals · 2026Review
- A comprehensive review of artificial intelligence for pharmacology research.Frontiers in genetics · 2024Review
- Ensemble Machine Learning Approaches Based on Molecular Descriptors and Graph Convolutional Networks for Predicting the Efflux Activities of MDR1 and BCRP Transporters.The AAPS journal · 2023Article
- Artificial Intelligence in Drug Metabolism and Excretion Prediction: Recent Advances, Challenges, and Future Perspectives.Pharmaceutics · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimization of compound metabolic stability is a highly topical issue in pharmaceutical research. Accordingly, application of predictive in silico models can potentially reduce the number of design-make-test-analyze iterations and consequently speed up the progression of novel candidate molecules. Herein, we have investigated the question if multiple in vitro clearance endpoints could be accurately predicted from image-based molecular representations. Thus, compound measurements for four commonly investigated clearance endpoints were curated from AstraZeneca internal sources, providing a sound basis for building multi-task convolutional neural network models. Application of several increasingly challenging data splitting strategies confirmed that convolutional neural network models were successful at capturing implicit chemical relationships contained in training and test data, similar to what is commonly observed for structural fingerprints. Furthermore, model benchmarking against state-of-the-art machine learning methods, including deep neural networks and graph convolutional neural networks, trained with structure- and graph-based representations, respectively, revealed on par or increased accuracy of convolutional neural networks with clear benefit of multi-task learning across all clearance endpoints. Our findings indicate that image-based molecular representations can be applied to predict multiple clearance endpoints, suggesting a potential follow-up to investigate model interpretability from molecular images.
Indexed as
Identifiers
35618861What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.